Press releases

All Press releases are available in Swedish.

Cyxone's development substance T20K's capacity to prevent and inhibit multiple sclerosis in animal models now verified by independent study

Cyxone can announce today that an independent research group at Monash University in Australia has confirmed the positive effects of the company's development substance T20K on multiple sclerosis (MS) symptoms in animal models as previously described.

Cyxone's development programme includes the confirmation of the positive results achieved with T20K on MS in animal models that a research group at the Medical University of Vienna outlined in an article published in March 2016 in the respected PNAS scientific journal and elsewhere. It is standard procedure ahead of clinical trials to allow independent laboratories to confirm the effectiveness of a new drug that is intended to be developed into a competitive product.

The research group investigated whether T20K, through pre-treatment of animals with a single dose administered seven days before initiation of the disease, could prevent the animals from developing MS symptoms, and that daily treatment with T20K after initiation, could prevent the development of MS.

The study showed that only one dose of either 5 or 10 mg/kg of T20K seven days prior to the initiation of the disease significantly delayed the development of symptoms, reduced the extent of MS symptoms, and significantly reduced the overall development of the illness in the animals.

When the test animals were started on an oral treatment of T20K at the same time as the disease was initiated, T20K delayed and reduced the development of symptoms even at 1mg/kg/day. With a dose of 3mg/kg/day, the animals displayed no measurable MS symptoms. The positive control substance Fingolimod (Gilenya) applied at the same 3mg/kg/day dose, showed similar effects on MS symptoms as T20K.

The results from Monash University thereby confirm that T20K has both the capacity to prevent MS, and to treat existing MS. The new study also shows that T20K works at considerably lower doses than previously described. Complete inhibition of MS symptoms takes place with an oral dose of 3mg/kg/day, compared to the previous effective oral dose of 20mg/kg/day.

The results suggest that T20K has a very competitive effect on MS compared to today's leading MS product, Gilenya; and that the safety interval appears to be even greater than previously achieved.

Cyxone's CEO, Kjell Stenberg, says: "Although we never doubted the findings of the research group at the Medical University of Vienna, we're delighted that it's been demonstrated that T20K performs even better against MS in animal models than we had previously thought, which provides encouragement for our work in studying T20K's effects on humans." Cyxone's chairman, Bert Junno, says: "The new results from the Australian laboratory strengthens Cyxone's leading position in the development of safer more effective MS treatments."

March 10, 2017

Contact
Cyxone AB (publ.)
Kjell G. Stenberg, CEO
Tel: +46 (0) 723 816 168
Email: kjell.g.stenberg@cyxone.com
Adelgatan 21
211 22 Malmö
www.cyxone.com

This is information that Cyxone AB is required to publish under the EU Market Abuse Directive. The information was provided under the auspices of the above contact person for publication on March 10, 2017 at 13:00 CET.

About Cyxone
Cyxone AB (publ.) is a biopharmaceutical company that develops drugs based on cyclotides, a class of natural plant protein. Cyclotide technology has the potential to provide new drugs with beneficial pharmacological effects on diseases that currently lack safe and effective treatments. The company is focusing on the development of T20K, a substance that inhibits key processes in cells that are typically associated with various immune disorders, such as multiple sclerosis and rheumatoid arthritis. Cyxone's Certified Adviser on the Nasdaq First North is Erik Penser Bank.

November 06, 2017
Regulatory

Cyxone has analysed the Rabeximod that was previously manufactured by OxyPharma for clinical trials at Syntagon AB. Results show that the existing substance, despite having been stored for several years, can be used in Cyxone's upcoming Phase 2b study in patients with rheumatoid arthritis.

Read more
October 26, 2017
Regulatory

Summary

Period (July 1 to September 30, 2017)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -1,518 (-1,235)
  • Earnings per share SEK -0,10 (-0,10) Cash and cash equivalents as of September 30 KSEK 25,662 (23,468)
  • Equity ratio as of September 30 95.2% (97.7%)

Period (January 1 to September 30)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -5,593 (-2,860)
  • Earnings per share SEK -0,36 (-0,22)
Read more
October 26, 2017
Regulatory
In co-operation with Taiwan-based Eurofins Panlabs Discovery Services, Cyxone has investigated whether T20K has the capacity to influence receptors or other cellular functions to shed light on the substance's potential side effects.
Read more
October 13, 2017
Regulatory

In collaboration with the Medical University of Vienna, Cyxone is set to conduct a study into inflammatory bowel disease involving a cyclotide in established animal models. The study will begin early in 2018.

Read more
October 06, 2017
Regulatory

Cyxone has licensed patent applications at various stages of approval in Europe, North America and Australia. In the US, our patent is approved and in other markets patent applications are well on the way to being approved. In Australia, our patent application was accepted in July, since when the company has submitted a final version and paid the required approval fee. 

Read more
October 05, 2017
Regulatory

Due to the interview conducted with Cyxone's CEO by BioStock/Monocl on Thursday, September 28, the company wishes to clarify references made about the extent to which two Phase 2 trials may be equated with a Phase 3 trial.

Read more
October 05, 2017
Regulatory

The subscription period to purchase warrants in TO 2 ended on September 29, 2017, and during the period, 2,467,119 warrant options were exercised for the equivalent number of shares, corresponding to a subscription ratio of around 98.7%. Cyxone thereby receives some SEK 12.3 million before issue costs.

Read more
August 30, 2017
Regulatory

Summary of interim report

Period (2017-01-01-2017-06-30)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -4 075 (-1 626)
  • Earnings per share -0,27 (-0,13) SEK
  • Cash and cash equivalents, KSEK 28 114 (24 636) as of 2017-06-30
  • Equity ratio 95,2 (87,9) % as of 2017-06-30

Period (2017-04-01-2017-06-30)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -2 588 (-1 157)
  • Earnings per share SEK -0,17 (-0,09) 
Read more
June 14, 2017

Cyxone signs acquisition agreement for candidate drug in Phase 2 Cyxone can announce today that the company has signed an agreement pertaining to the exclusive rights to acquire the clinical candidate drug Rabeximod from OxyPharma AB. The transaction has been structured so as to minimise the impact on Cyxone's cash flow by offering the seller 1,916,372 shares, (one million, nine hundred and sixteen thousand, three hundred and seventy two shares amounting to a dilution of 12.5 per cent), as well as royalty rights amounting to ten (10) per cent of future net earnings from Rabeximod. Cyxone will call an extraordinary general meeting to seek shareholder approval for a directed new share issue. This will pave the way for the acquisition and a Phase 2b-study in rheumatoid arthritis.

Read more
June 07, 2017

Cyxone AB and the University of Queensland in Australia are launching a co- operation agreement to continue studies into the effects of Cyxone's T20K development substance in combating MS.

Read more
1
2